<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663208</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-004</org_study_id>
    <nct_id>NCT00663208</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects</brief_title>
  <official_title>Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of Daclatasvir in Subjects Infected With Hepatitis C Virus Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the change in Hepatitis C Virus RNA during
      dosing with daclatasvir and during the follow-up period in subjects with chronic hepatitis C
      infection
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline at Day 7 in log10 Hepatitis C Virus (HCV) RNA of All Participants</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Roche TaqMan HCV quantitative assay was used for analysis with detection limit of 10 IU/mL. Baseline was Day -1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Day 7 in log10 Hepatitis C Virus (HCV) RNA Levels of Participants Without Baseline Drug Resistance</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Roche TaqMan HCV quantitative assay was used for analysis with detection limit of 10 international units/ millilitre (IU/mL). Baseline was Day -1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 24 h Post Dose on Day 1 in log10 Hepatitis C Virus (HCV) RNA of Participants Without Baseline Drug Resistance</measure>
    <time_frame>Baseline, 2, 4, 6, 8, 12, 16, 20, and 24 hours post dose on Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Roche TaqMan HCV quantitative assay was used for analysis with detection limit of 10 IU/mL. Baseline was Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 4 in log10 Hepatitis C Virus (HCV) RNA in Participants Without Baseline Drug Resistance</measure>
    <time_frame>Baseline to Day 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Roche TaqMan HCV quantitative assay was used for analysis with detection limit of 10 IU/mL. Baseline was Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 14 in Log10 Hepatitis C Virus (HCV) RNA in Participants Without Baseline Drug Resistance</measure>
    <time_frame>Baseline to Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Roche TaqMan HCV quantitative assay was used for analysis with detection limit of 10 IU/mL. Baseline was Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Decline From Baseline in Hepatitis C Virus (HCV) RNA in Participants Without Baseline Drug Resistance</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants without baseline drug resistance were assessed for time to reach maximum decrease in log10 HCV RNA level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Decline From Baseline in Log10 Hepatitis C Virus (HCV) RNA in Participants Without Baseline Drug Resistance</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Roche TaqMan HCV quantitative assay was used for analysis with detection limit of 10 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Cmin) of Daclatasvir on Days 1 and 14</measure>
    <time_frame>0 hour (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours (post morning dose) at Day1 and Day 14, 0 hour (pre-dose) at Days 2, 3, 4, 5, 7, 9, 11, 13 and 24, 48 and 72 hours (post morning dose) at Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>The peak concentrations in plasma (Cmax) and minimum observed plasma concentration (Cmin) were defined as the peak maximum and minimum plasma level of daclatasvir, derived from plasma concentration-time data analyzed by non-compartmental methods. Cmax and Cmin of daclatasvir in plasma was assayed using a validated liquid chromatography tandem mass spectrometry method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) in 1 Dosing Interval of Daclatasvir at Days 1 and 14</measure>
    <time_frame>0 hour (pre-dose) 0.5, 1,1.5, 2, 3, 4, 6, 8 and 12 hours (post morning dose) at Day1 and Day 14, 0 hr (pre-dose) at Days 2, 3, 4, 5, 7, 9, 11, 13, and 24, 48 and 72 hours (post morning dose) at Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>The area under the concentration-time curve in 1 Dosing Interval AUC(TAU) was used to measure the drug exposure over 1 dosing interval., derived from plasma concentration-time data analyzed by non-compartmental methods. AUC(TAU) of daclatasvir in plasma was assayed using a validated liquid chromatography tandem mass spectrometry method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Half-life (T-half) of Daclatasvir at Day 14</measure>
    <time_frame>0 hour (pre-dose) 0.5, 1,1.5, 2, 3, 4, 6, 8 and 12 hours (post morning dose) at Day1 and Day 14, 0 hr (pre-dose) at Days 2, 3, 4, 5, 7, 9, 11, 13, and 24, 48 and 72 hours (post morning dose) at Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>The absolute values of lamda (λ) were used to evaluate apparent terminal half-life (T-half) was defined as T-half= ln 2/λ. T-half was derived from plasma concentration-time data analyzed by non-compartmental methods. T-half of daclatasvir in plasma was assayed using a validated liquid chromatography tandem mass spectrometry method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance (CLT/F) of Daclatasvir on Day 14</measure>
    <time_frame>0 hour (pre-dose) 0.5, 1,1.5, 2, 3, 4, 6, 8 and 12 hours (post morning dose) at Day1 and Day 14, 0 hour (pre-dose) at Days 2, 3, 4, 5, 7, 9, 11, 13, and 24, 48 and 72 hours (post morning dose) at Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>The apparent total body clearance at steady state (CLT/F) was defined as the apparent body clearance of canakinumab from the serum when the systemic availability was unknown. CLT/F was derived from plasma concentration-time data analyzed by non-compartmental methods. CLT/F of daclatasvir in plasma was assayed using a validated liquid chromatography tandem mass spectrometry method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Observed Plasma Concentration (Css-av) at Steady State of Daclatasvir at Days 1 and 14</measure>
    <time_frame>0 hour (pre-dose) 0.5, 1,1.5, 2, 3, 4, 6, 8 and 12 hours (post morning dose) at Day1 and Day 14, 0 hr (pre-dose) at Days 2, 3, 4, 5, 7, 9, 11,13, and 24, 48 and 72 hours (post morning dose) at Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>The average observed plasma concentration at steady state (Css-av) was calculated as ratio of AUC(TAU) by TAU, where TAU = 24 h for QD dosing and 12 h for BID dosing. Css-av was derived from plasma concentration-time data analyzed by non-compartmental methods. Css-av of daclatasvir in plasma was assayed using a validated liquid chromatography tandem mass spectrometry method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index (AI) AUC(TAU), AI Cmax, and Degree of Fluctuation (DF) of Daclatasvir on Day 14</measure>
    <time_frame>0 hour (pre-dose) 0.5, 1,1.5, 2, 3, 4, 6, 8 and 12 hours (post morning dose) at Day1 and Day 14, 0 hour (pre-dose) at Days 2, 3, 4, 5, 7, 9, 11, 13, and 24, 48 and 72 hours (post morning dose) at Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>Accumulation index area under the concentration-time curve of daclatasvir to the end of the dosing period [AI AUC(TAU)] was defined as the ratio of AUC(TAU) at steady-state to AUC(TAU) after the first dose.Accumulation index maximum observed concentration of daclatasvir in plasma (AI Cmax) was defined as the ratio of Cmax at steady-state to Cmax after the first dose. Degree of Fluctuation (DF) was defined as the ratio of difference between Cmax and Cmin at steady state by Css-av. The parameters were analyzed using non-compartmental methods, assayed by validated liquid chromatography tandem mass spectrometry (LC-MS/MS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir on Days 1 and 14</measure>
    <time_frame>0 hour (pre-dose) 0.5, 1,1.5, 2, 3, 4, 6, 8 and 12 hours (post morning dose) at Day1 and Day 14, 0 hour (pre-dose) at Days 2, 3, 4, 5, 7, 9, 11, 13, and 24, 48 and 72 hours (post morning dose) at Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax was defined as the time to reach maximum observed plasma concentration of daclatasvir in plasma. Tmax was derived from plasma concentration-time data analyzed by non-compartmental methods. Tmax of daclatasvir in plasma was assayed using a validated liquid chromatography tandem mass spectrometry method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Coefficients Between Measures of Decline in log10 Hepatitis C Virus (HCV) RNA and Daclatasvir PK Parameters Cmax, AUC(TAU), and Cmin on Day 14 in Participants Without Baseline Drug Resistance</measure>
    <time_frame>Day 4, Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation between decline of log10 hepatitis C virus (HCV) RNA and exposure to study drug was measured by Pearson Correlation Coefficients. The change from baseline at Day 4 in log10 HCV RNA and the maximum decline in log10 HCV RNA were evaluated against the PK parameters Cmax, Cmin and AUC(TAU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuation Due to Adverse Events (AEs), and Who Died</measure>
    <time_frame>Day 1 to Day 182 or Day of Discharge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Laboratory Abnormalities in Hematology</measure>
    <time_frame>Screening, Day 3, Day 7, Day 11, Day 14, and Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hematology marked laboratory abnormalities were defined as Hemoglobin (g/dL) Low as &lt; 0.85*Pre-therapy (PreRx), Hematocrit (%) Low as &lt; 0.85*PreRx, Platelet Count *10^9 c/L Low as &lt; 0.85*Lower Limits of Normal (LLN) if PreRx = Missing/&lt; 0.85*LLN if PreRx &gt;= LLN/&lt; 0.85*PreRx if PreRx &lt; LLN, Eosinophils (absolute) *10^3 c/µL High as &gt; 0.75*count, Leukocytes White Blood Cell (WBC) *10^3 c/µL High as &gt; 1.2*ULN if LLN &lt;= PreRx &lt;= Upper Limits of Normal (ULN) &gt; 1.2*ULN if PreRx = Missing/&gt; 1.5*PreRx if PreRx &gt; ULN/&gt; ULN if PreRx &lt; LLN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Abnormalities in Liver and Kidney Function Laboratory Tests and Electrolytes</measure>
    <time_frame>Screening, Day 3, Day 7, Day 11, Day 14, and Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Liver and kidney function marked laboratory abnormalities were defined as Alanine Aminotransferase (ALT) units per liter (U/L) High as &gt; 1.25*PreRx if PreRx &gt; ULN/&gt; 1.25*ULN if PreRx &lt;= ULN/&gt; 1.25*ULN if PreRx = Missing, Aspartate Aminotransferase (AST) U/L High as &gt; 1.25* PreRx if PreRx &gt; ULN/&gt; 1.25*ULN if PreRx &lt;= ULN/&gt; 1.25*ULN if PreRx = Missing, Alkaline Phosphatase(ALP)U/L High as &gt; 1.25*PreRx if PreRx &gt; ULN/&gt; 1.25*ULN if PreRx &lt;= ULN/&gt; 1.25*ULN if PreRx = Missing, G-Glutamyl Transferase (GGT) in U/L High as &gt;1.15*ULN if PreRx&lt;=ULN/&gt;1.15* if PreRx missing/&gt;1.2* PreRx if PreRx&gt;ULN, Phosphorus Inorganic (mg/dL) Low as &lt; 0.85*LLN if LLN &lt;= PreRx &lt;= ULN/&lt; 0.85*LLN if PreRx = Missing/&lt; 0.85*PreRx if PreRx &lt; LLN/&lt; LLN if PreRx &gt; ULN, and Potassium serum milliequivalents per liter (mEq/L) High as &gt; 1.1*PreRx if PreRx &gt; ULN/&gt; 1.1*ULN if LLN &lt;= PreRx &lt;= ULN/&gt; 1.1*ULN if PreRx = Missing/&gt; ULN if PreRx &lt; LLN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Laboratory Abnormalities in Lipase and Glucose</measure>
    <time_frame>Screening, Day 3, Day 7, Day 11, Day 14, and Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Marked abnormalities were defined as Lipase (U/L) High as &gt;1.5*ULN, Glucose fasting serum (mg/dL) High as &gt; 1.3*ULN if LLN &lt;= PreRx &lt;= ULN/&gt; 1.3*ULN if PreRx = Missing/&gt;2*PreRx; if PreRx &gt; ULN/&gt; ULN if PreRx &lt; LLN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Laboratory Abnormalities in Urinalysis</measure>
    <time_frame>Screening, Day 3, Day 7, Day 11, Day 14, and Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Marked laboratory abnormalities in urinalysis were defined as, Blood Urine High as &gt;= 2*PreRx if PreRx &gt;= 1/&gt;= 2 if PreRx &lt; 1/&gt;= 2 if PreRx = Missing. Glucose Urine High as &gt;= 1 if PreRx &lt; 1/&gt;= 1 if PreRx = Missing/&gt;= 2*PreRx if PreRx &gt;= 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Change From Baseline in Vital Signs</measure>
    <time_frame>Screening, Day -1 and prior to morning dose on Day 1, 2, 14, and 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Vital signs included: body temperature, respiratory rate, blood pressure (systolic and diastolic) and heart rate. Blood pressure and heart rate were measured after the participant had been supine, semi-supine, or seated quietly for at least 5 minutes. Baseline was defined as the last observation prior to dosing on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting Pre-Specified Criteria in Electrocardiogram Parameters</measure>
    <time_frame>Screening, Day 2, 3, 5, 7, 9, 11, 13, 15, 21 and 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pre-specified criteria were defined as, Heart rate (HR) minimum as &lt;=50 bpm/change from baseline &lt;-20 bpm/maximum HR &gt;100 bpm, QT interval corrected using Fridericia's formula (QTcF) maximum as QTcF&lt;=450 msec/450 msec &lt;maximum QTcF and &lt;=480 msec/480 msec &lt;maximum QTcF &lt;= 500 msec/maximum QTcF&gt;500 msec, QRS interval as &lt;=120 msec/&gt;120 msec, and PR interval maximum as &lt;= 200 msec/&gt;200 msec.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daclatasvir (1 mg), once daily
or
Matching Placebo, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daclatasvir (10 mg), once daily
or
Matching Placebo, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daclatasvir (1-100 mg), once or twice daily
or
Matching Placebo, once or twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daclatasvir (1-100 mg), once or twice daily
or
Matching Placebo, once or twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 5: Active Comparator
Daclatasvir (1-100 mg), once or twice daily
or
Matching Placebo, once or twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 6: Active Comparator
Daclatasvir (1-100 mg), once or twice daily
or
Matching Placebo, once or twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Capsule, Oral, Approximately 182 days from initial dosing</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronically infected with Hepatitis C Virus (HCV) genotype 1

          -  Treatment naive or treatment non-responders or treatment intolerant; and not
             co-infected with HIV or Hepatitis B Virus

          -  HCV RNA viral load of ≥10*5 IU/mL

          -  BMI 18 to 35kg/m²

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness which is not stable or is not
             controlled with medication and not consistent with Hepatitis C Virus infection

          -  HIV and/or HBV positive

          -  Major surgery within 4 weeks of study drug administration and any gastrointestinal
             surgery that could impact the absorption of study drug

        WOCBP will be enrolled as in-patient for 16 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Res Inst</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Clinical Trials, Llc</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parexel International Corporation</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santurce</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 16, 2015</lastchanged_date>
  <firstreceived_date>April 18, 2008</firstreceived_date>
  <firstreceived_results_date>August 14, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
